Cross-border biotech deals between China and the United States are becoming more complicated and could face a modest slowdown as Washington steps up efforts to restrict investment and technology transfers, according to industry analysts. “There will be more geopolitical scrutiny going forward. This scrutiny may lead to slightly fewer deals than without it,” said Diederik Stadig, senior healthcare economist at ING Research. Despite the growing regulatory hurdles, Stadig said the broader trend of...
UPVOTERS
Community appreciation
See who found this content valuable and showed their support.
No upvotes yet.
Be the first to show your appreciation for this content.
TOPICS
Explore the same topics
Discover more content from the topics this post is mapped to.
Keep browsing
Explore more from this topic
Dive into the full feed of curated posts covering Automotive News & Trends.
Discussion
Don’t hold back—comment!
Don’t wait—start sharing your ideas now!